---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-001933"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:18:34.123191+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma announces 2024 strategic priorities; Phase 3 readouts in 3Q/4Q 2024

## Summary
- Expects topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024.
- Expects topline data from Phase 3 BROADWAY trial in ASCVD in 4Q 2024.
- Plans to initiate TANDEM Phase 3 FDC trial in 1Q 2024; topline data in 1Q 2025.
- Completes enrollment in PREVAIL CVOT in 1Q 2024; topline data in 2026.
- Cash sufficient to fund operations through 2026, beyond three Phase 3 readouts.

## SEC filing metadata
- accession: 0001193125-24-001933
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524001933/0001193125-24-001933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524001933/d822244d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-001933
- JSON: https://secwatch.observer/filing/0001193125-24-001933.json
- Plain text: https://secwatch.observer/filing/0001193125-24-001933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.